6/1
08:19 am
ppbt
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer [Yahoo! Finance]
6/1
08:00 am
ppbt
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Medium
Report
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
5/21
12:18 pm
ppbt
Purple Biotech Ltd (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Purple Biotech Ltd (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
5/21
07:44 am
ppbt
Purple Biotech Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Purple Biotech Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/21
07:30 am
ppbt
Purple Biotech Reports First Quarter 2024 Financial Results
Medium
Report
Purple Biotech Reports First Quarter 2024 Financial Results
4/26
02:35 pm
ppbt
Purple Biotech Ltd. (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Purple Biotech Ltd. (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
4/25
07:12 am
ppbt
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting [Yahoo! Finance]
4/25
07:00 am
ppbt
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
High
Report
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
3/28
07:09 am
ppbt
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 [Yahoo! Finance]
Medium
Report
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 [Yahoo! Finance]
3/28
07:00 am
ppbt
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
Medium
Report
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024